NCLT Clears Shilpa Therapeutics-Shilpa Medicare Merger; Subsidiary Expands to Latin America

• NCLT Bengaluru Bench approved the amalgamation of Shilpa Therapeutics Private Ltd with its parent company, Shilpa Medicare Ltd, based on an order dated February 27, 2026.
• The merger will become effective upon filing certified copies of the NCLT order with the Registrar of Companies and fulfilling other specified conditions.
• Shilpa Biologicals Pvt. Ltd., a material subsidiary, entered a licensing agreement with SteinCares to commercialise a biosimilar across Latin America.
• This partnership marks Shilpa Biologicals' entry into the Latin American market, combining Shilpa's development capabilities with SteinCares' regional platform.
• Shilpa Medicare shares closed up 3.85% at ₹328.00 on the BSE following these significant developments.